-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOMEA FUSION ANNOUNCES FIRST PATIENT DOSED IN OPAL STUDY EVALUATING ICOVAMENIB IN COMBINATION WITH SEMAGLUTIDE IN OBESITY

Reuters·08/13/2026 11:00:02

Please log in to view news